Business Wire

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening


Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM. This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.

Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology. Recent posters presented at the AACR annual meeting and ANE international conference 2023 demonstrate the performance of assay-ready organoids against freshly prepared organoids – the traditional methodology. The study demonstrated the utility of OrganoidXplore and revealed:

  • Highly Robust Performance: Both the assay-ready and original methods consistently performed with high accuracy across multiple assays.
  • Accelerated Timelines and Reduced Costs: OrganoidXplore slashed project timelines by two-thirds, when compared to standard methods.
  • Reliable and Reproducible Drug Response Comparisons: Both methods showed analogous results in cell viability (CTG) and high content imaging (HCI) assays when tested with standard drugs such as paclitaxel, carboplatin, and cisplatin.

OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening. By accurately replicating the genomic, morphological, and pathophysiological attributes of original tumors, researchers are now equipped to screen against an extensive range of predictive models. Results can be obtained within an expedited timeframe of just six weeks, magnifying research speed three-fold and anchoring its promise on the robustness and reproducibility of its advanced assay-ready technology.

Researchers can choose between a comprehensive Full Panel or a specialized KRAS Panel to meet their specific goals. The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX). The KRAS Panel specifically targets four cancer indications, with 25 models covering a broad range of KRAS mutations. These models are also available as PDX, allowing for a seamless transition to follow-on studies.

In combination with comprehensive next-generation sequencing (NGS) characterization, including whole exome sequencing (WES) and RNA sequencing (RNAseq), OrganoidXplore enables expedited biomarker identification, highly relevant mechanism of action studies, selection of indications and/or models, investigation of drug repurposing, and improved patient stratification.

Leo Price, PhD, Senior Vice President, In Vitroand Head of Crown Bioscience Netherlands, said: “OrganoidXplore addresses the exacting demands of pioneering research initiatives by offering a diverse selection of models that cover a wide spectrum of genetic backgrounds and mutations. Thanks to the implementation of innovative organoid cryopreservation technology automation and assay automation, OrganoidXplore’s precision, speed, and reproducibility are unrivaled.”

Crown Bioscience remains steadfast in its commitment to driving innovations in oncology research, evidenced by the introduction of OrganoidXplore, designed with the mission to accelerate drug discovery.


About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology and immuno-oncology. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology, offering over 600 organoid models spanning 22 cancer indications. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia.

For more information or to get in touch, please visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Evolito First in UK to Secure CAA Design Organisation Approval for Electric Propulsion Systems5.12.2023 09:00:00 CET | Press release

Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics and battery solutions for aerospace applications, has received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products. This press release features multimedia. View the full release here: Evolito’s D500 Axial Flux Motor: stacked for increased torque and power up to 1 megawatt. (Photo: Business Wire) The UK Civil Aviation Authority’s approval of Evolito as a Design Organisation demonstrates that it is satisfied that Evolito has the technical expertise, facilities and capabilities to design safe and reliable products, and is able to comply with stringent requirements for certification. Evolito is the first company in the UK to achieve this for electric propulsion systems. This accreditation is a significant milestone towards certification of Evolito’s products, as well as supporting cu

PUMA Scale-up Their Textile-to-textile Recycling Technology, Creating All Future Replica Football Kit Using RE:FIBRE Technology5.12.2023 09:00:00 CET | Press release

Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. This press release features multimedia. View the full release here: Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. (Photo: Business Wire) Since the launch of the pilot in 2022, which saw PUMA produce recycled training jerseys for their sponsored football clubs, RE:FIBRE technology has been used to create Switzerland and Morocco replica kits for the Women’s World Cup as well as Girona’s 2023/24 season Third kit. In 2024, official PUMA football replica jerseys* including those for the Euro and Copa A

Taulia Adds Bank of China and BNP Paribas to Its Funder Network5.12.2023 09:00:00 CET | Press release

Taulia, a leading provider of working capital management solutions, today announced it has added the Bank of China London Branch, and BNP Paribas to its global multi-funder network. The addition of the two major global banks is the most recent in an already large and growing network of funders available to Taulia’s global customers, enabling businesses to access an increasingly broad and diverse funding pool, with greater choice, liquidity, and availability of capital. Multifunder models within supply chain finance programs are designed to provide resilience through diversification and a wider pool of funding for different currencies, geographies, client sizes, and credit profiles. Combined with the right technology, it also enables businesses to hedge against liquidity risk, particularly during periods of economic uncertainty. Cedric Bru, CEO, Taulia, comments: “Adding Bank of China and BNP Paribas to the Taulia multi-funder network is an enormous achievement, and we are delighted to

FPT Software Joins Global Tech Giants in the AI Alliance as Founding Member5.12.2023 07:00:00 CET | Press release

FPT Software, a global leading IT provider, announced its participation in the AIAlliance, a pivotal initiative formed by leading organizations across industry, startup, academia, research, and government with a shared goal of supporting open innovation and open science in AI. The alliance is expected to advance AI collaboration and foster innovation across all aspects of AI technology, applications, and governance. This press release features multimedia. View the full release here: FPT Software Participates in the AI Alliance with Other Global Tech Giants (Photo: Business Wire) The Alliance, co-launched by IBM and Meta in collaboration with Founding Members globally, aims to leverage a critical mass of computing, data, tools, and talent to accelerate open innovation in AI to build and support open technologies across software, models, and tools, which empower students, developers, and scientists to understand and embrace open t

Wallarm Reveals Current Threats to API Security, Move to 100% Channel Strategy and New API Attack Management Solution at Black Hat Europe 20235.12.2023 07:00:00 CET | Press release

BLACK HAT EUROPE 2023 –Wallarm, the integrated app and API security company, today announced its upcoming appearance at Black Hat Europe 2023, the Dec. 4 to Dec. 7 conference that provides the latest in research, development and trends in information security. Wallarm executives are hosting a session on Dec. 7 at 12:15 p.m. GMT at ExCeL London and sharing critical insights and recommendations from the latest API ThreatStats™ report. Additionally, Wallarm is discussing its new 100% channel strategy and launching a new API Attack Surface Management solution during Black Hat Europe. Wallarm’s Black Hat appearance comes as interest in API security solutions grows in Europe, with the Europe API security market expected to witness market growth of 31.5% CAGR during the forecast period (2023-2030). This critical opportunity allows Wallarm to build awareness around the need for API and app security, jump-start expansion to the European market and recruit additional channel partners. Key announ